NRXS · Neuraxis, INC
$6.21
-0.09 (-1.43%)
At close · Aug 17
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Neither future cash generated from operating activities, nor management's contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable. As a result, substantial doubt is deemed to exist about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 11, 2026
Market Cap
$79.11M
Shares
12.56M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.30
Open$6.46
Day$6.20–6.51
52W close$2.31–8.81
Avg vol 30d87K
Short int418K · 3.3% float · 5.0d
Short vol60%
Last earningsAug 11, 2026
DataAug 2023–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 29, 2026
Est · unconfirmed
· in 15 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+11%
above
Price vs 50-day avg
−8%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
61%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+33%
trailing
YTD return
+39%
this year
Relative strength
+19%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.33% of float · ▼ -11.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+33%
Y/Y
Gross margin
84%
contracting
EPS growth
+22%
Y/Y
Free cash flow
$-6.5M
Balance sheet
$4.6M
net cash
Quant / Vol
risk profile
Volatility
74%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+11%
Bullish
Price vs 50-day avg
−8%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
61%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $7 › 200d $6 — 50d above 200d
Institutional flow
Accumulating
+23% holders QoQ · +9 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.33% of float · ▼ -11.3% MoM · 5.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
32 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2
Now $6 · 61%
Range high $9
vs 200-day avg +11%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRXS
this stock
Neuraxis, INC
|
$79.11M | +38.8% | +32.9% | — | 3.3% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRXS | -11.1% | -6.7% | +32.6% | +0.8% | +38.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -11.5% | -11.1% | +18.9% | -3.1% | +24.9% |
Key facts
CIK
1933567
CUSIP
64134X201
13F (30d)
31 filings
31 filers
Visit website
Investor relations